FSL Q4 PBT Hits ₹2.6B; FY27 Guidance Set at 13% Revenue Growth

Market snapshot: Firstsource Solutions (FSL) has demonstrated resilient growth in the fourth quarter, reporting a consolidated Profit Before Tax (PBT) of ₹2.6B, a sequential increase from ₹2.5B. This steady profitability is complemented by an optimistic FY27 outlook, which projects double-digit revenue growth and improved EBIT margins. The market is reacting to this forward-looking visibility, which suggests that the company’s strategic transition toward AI-led operations is beginning to materialize in its financial performance.

Data Snapshot

• Q4 PBT: ₹2.6B (vs ₹2.5B QoQ)
• FY27 Rev Growth: 10-13% Constant Currency
• FY27 EBIT Margin: 12.25-12.75% Band
• FY26 Annual Revenue: Crossed $1 Billion Milestone

What's Changed

• Sequential Profitability Rise: PBT expanded from ₹2.5B to ₹2.6B, indicating efficient operational scaling.
• Guidance Upgrade: The 10-13% CC growth guidance for FY27 reflects a higher baseline compared to previous conservative estimates.
• Margin Stability: Guidance of 12.25-12.75% EBIT margin suggests that recent AI investments are not diluting profitability.

Key Takeaways

• FSL has successfully reached the $1B revenue club in FY26, fundamentally altering its market valuation logic.
• Strong Q4 deal pipeline conversion has led to a growth guidance that exceeds the general IT industry average for the next fiscal.
• The 'Intelligence That Operates' strategy, backed by the Kairos OS launch, is now a primary driver of client acquisitions and renewals.

SAHI Perspective

FSL is moving away from traditional labour-arbitrage BPO models toward a high-value 'UnBPO' framework. By setting a guidance of up to 13% growth when larger peers are struggling with single digits, FSL is positioning itself as a high-performance specialist in BFSI and Healthcare. The margin expansion to 12.75% is particularly critical as it demonstrates that the company is managing its recent TeleMedik acquisition costs effectively while investing in its AI operating system, Kairos.

Market Implications

The positive guidance is likely to trigger institutional re-rating as analysts adjust FY27 EPS estimates upward. Sector-wide, it signals that BPM players with strong AI integration are decoupling from the slower growth observed in traditional IT services. Capital allocation signals suggest continued investment in clinical capabilities and AI-native delivery platforms.

Trading Signals

Market Bias: Bullish

Consistent QoQ profit growth of 4% and a robust 13% revenue growth target for FY27 provide a high margin of safety for valuation.

Overweight: IT-BPM, Healthcare Tech, BFSI Services

Underweight: Traditional Outsourcing

Trigger Factors:

• Quarterly EBIT margin crossing 12.5%
• Stabilization of US BFSI deal conversion rates
• Successful integration of TeleMedik clinical workflows

Time Horizon: Medium-term (3-12 months)

Industry Context

The global BPM industry is currently undergoing a structural shift where AI-led 'agentic' workflows are replacing traditional headcount-based billing. FSL's focus on Healthcare and BFSI—two sectors with high regulatory hurdles and deep clinical/domain requirements—provides it with a moat against commoditized competition. Peer performance suggests that only those with niche vertical focus are managing double-digit growth in the current macro climate.

Key Risks to Watch

• Potential slowdown in US healthcare payer spending due to regulatory shifts.
• Currency volatility impacting the Constant Currency translation gains.
• Higher-than-expected attrition in specialized clinical roles following acquisitions.

Recent Developments

On April 16, 2026, FSL launched 'Kairos,' a full-stack AI operating system designed to automate agent workflows. In January 2026, the company completed the acquisition of TeleMedik, bolstering its presence in the U.S. Medicaid and Medicare Advantage markets. These moves follow the company's entry into the $1 billion revenue club for the fiscal year ended March 31, 2026.

Closing Insight

Firstsource Solutions is entering FY27 with high visibility and a revamped technological core. The combination of profitability growth and an aggressive revenue target makes it a standout performer in the mid-cap IT space.

FAQs

What does the 10-13% CC revenue guidance mean for the company's valuation?

This guidance suggests FSL is expected to outpace the industry average. At a growth rate of 13%, the company is likely to see valuation multiple expansion as it proves its AI-led growth model is sustainable.

How will the acquisition of TeleMedik affect the FY27 EBIT margins?

Management has baked the integration costs into the 12.25-12.75% EBIT margin guidance. This suggests the acquisition will be margin-accretive or neutral by the second half of FY27 as synergies in healthcare clinical services are realized.

Is the increase in Q4 PBT to ₹2.6B a sign of better cost management?

Yes, the QoQ increase from ₹2.5B indicates that FSL is gaining operational leverage. The launch of the Kairos AI system likely contributed to lower manual intervention costs, boosting the bottom line despite stagnant macro conditions.

High Performance Trading with SAHI.